Biogen (MEX:BIIB) Ending Cash Position

: MXN52,240 Mil (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

Biogen's Ending Cash Position for the quarter that ended in Mar. 2023 was MXN52,240 Mil.

Biogen's quarterly Ending Cash Position declined from Sep. 2022 (MXN73,935 Mil) to Dec. 2022 (MXN66,663 Mil) and declined from Dec. 2022 (MXN66,663 Mil) to Mar. 2023 (MXN52,240 Mil).

Biogen's annual Ending Cash Position increased from Dec. 2020 (MXN26,480 Mil) to Dec. 2021 (MXN46,390 Mil) and increased from Dec. 2021 (MXN46,390 Mil) to Dec. 2022 (MXN66,663 Mil).

Biogen Ending Cash Position Historical Data

The historical data trend for Biogen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Ending Cash Position

24,045.02

54,952.38

26,480.23

46,390.36

66,662.67

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Ending Cash Position																34,830.31	53,244.30	73,934.69	66,662.67	52,240.06

Biogen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biogen's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	44088.254	+	22574.419
	=	66,663

Biogen's Ending Cash Position for the quarter that ended in Mar. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	61632.883	+	-9392.828
	=	52,240

Biogen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Biogen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.